Evidence map›Paper›PMID 40424263›Full record

ArticlePloS one2025

Antiviral potential of proton-type zeolite.

Yuka Kimura, Masanori Takemoto, Noriko Nakamura, Takeshi Ichinohe, Makoto Nakakido, Kenta Iyoki, Seiichi Ohta, Nobuhiro Miyamae, Yuki Egami, Koichi Sato and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yuka KimuraDepartment of Chemical System Engineering, The University of Tokyo, Japan.
Masanori TakemotoDepartment of Chemical System Engineering, The University of Tokyo, Japan.ORCID https://orcid.org/0000-0002-3043-5676
Noriko NakamuraDepartment of Chemical System Engineering, The University of Tokyo, Japan.
Takeshi IchinoheDepartment of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Japan.
Makoto NakakidoDepartment of Bioengineering, The University of Tokyo, Japan.
Kenta IyokiDepartment of Chemical System Engineering, The University of Tokyo, Japan.
Seiichi OhtaDepartment of Chemical System Engineering, The University of Tokyo, Japan.
Nobuhiro MiyamaeNippon Paint Co., Ltd, Japan.
Yuki EgamiNippon Paint Co., Ltd, Japan.
Koichi SatoNippon Paint Co., Ltd, Japan.
Tatsuya OkuboDepartment of Chemical System Engineering, The University of Tokyo, Japan.
Kouhei TsumotoDepartment of Bioengineering, The University of Tokyo, Japan.
Toru WakiharaDepartment of Chemical System Engineering, The University of Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study reports the potent antiviral ability of proton-type zeolites without the aid of any metal cations. Antiviral activities of zeolites with different topologies and chemical compositions are investigated using M13 phage and influenza virus. Proton-type zeolites exhibit excellent antiviral activity, equivalent to 99% inactivated. Antiviral tests using a centricon device suggest that direct contact of viruses on the external surface of zeolites is required to inactivate the viruses. This discovery is of importance in an interdisciplinary research field covering both zeolite science and virological science and shed light on the possibility of the development of low-cost and environmentally friendly antiviral zeolites.

Indexed as

Antiviral AgentsZeolitesOrthomyxoviridaeProtonsAntiviral AgentsProtonsZeolites

Identifiers

PMID40424263
PMCPMC12111268

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.